![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » HEMISPHERX BIOPHARMA TO BEGIN AMPLIGEN TRIAL
HEMISPHERX BIOPHARMA TO BEGIN AMPLIGEN TRIAL
May 15, 2006
Hemispherx Biopharma has reported that it will begin an Ampligen immunopotentiation clinical trial. The Phase II clinical trial will be conducted in Australia.
Recent preclinical studies suggest that Ampligen, an experimental immunotherapeutic, may achieve at least two major therapeutic benefits when co-administered with other influenza vaccines.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct